This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, C. Articles by Tisdale, M. Search for Related Content PubMed PubMed Citation Articles by Stone, C. Articles by Tisdale, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information AIDS Medicines

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2004, p. 1413-1415, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1413-1415.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine

Chris Stone,¹ Mounir Ait-Khaled,² Charles Craig,^1* Philip Griffin,¹ and Margaret Tisdale¹

International Clinical Virology, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY,¹ Clinical Development and Medical Affairs, GlaxoSmithKline, Greenford, Middlesex, United Kingdom²

Received 28 August 2003/ Returned for modification 14 October 2003/ Accepted 18 December 2003

Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.

---

* Corresponding author. Mailing address: International Clinical Virology, GlaxoSmithKline, Gunnel's Wood Rd., Stevenage, Hertfordshire, SG1 2NY, United Kingdom. Phone: 44 (0) 1707-763919. Fax: 44 (0) 1707-764263. E-mail: charles.j.craig{at}gsk.com.

---

Antimicrobial Agents and Chemotherapy, April 2004, p. 1413-1415, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1413-1415.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Margot, N. A., Waters, J. M., Miller, M. D. (2006). In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine. Antimicrob. Agents Chemother. 50: 4087-4095 [Abstract] [Full Text]  
• Doualla-Bell, F., Avalos, A., Brenner, B., Gaolathe, T., Mine, M., Gaseitsiwe, S., Oliveira, M., Moisi, D., Ndwapi, N., Moffat, H., Essex, M., Wainberg, M. A. (2006). High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens. Antimicrob. Agents Chemother. 50: 4182-4185 [Abstract] [Full Text]  
• Parikh, U. M., Bacheler, L., Koontz, D., Mellors, J. W. (2006). The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations.. J. Virol. 80: 4971-4977 [Abstract] [Full Text]  
• Wainberg, M. A., Brenner, B. G., Turner, D. (2005). Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1671-1678 [Full Text]